APA (7th ed.) Citation

RL, K., MM, B., E, R., L, C., L, W., K, H., . . . SK, F. (2025). CFTR modulator therapy drives microbiome restructuring through improved host physiology in cystic fibrosis: The IMMProveCF phase IV trial. Nature communications, 16(1), 10111. https://doi.org/10.1038/s41467-025-64218-z

Chicago Style (17th ed.) Citation

RL, Knoll, et al. "CFTR Modulator Therapy Drives Microbiome Restructuring Through Improved Host Physiology in Cystic Fibrosis: The IMMProveCF Phase IV Trial." Nature Communications 16, no. 1 (2025): 10111. https://doi.org/10.1038/s41467-025-64218-z.

MLA (9th ed.) Citation

RL, Knoll, et al. "CFTR Modulator Therapy Drives Microbiome Restructuring Through Improved Host Physiology in Cystic Fibrosis: The IMMProveCF Phase IV Trial." Nature Communications, vol. 16, no. 1, 2025, p. 10111, https://doi.org/10.1038/s41467-025-64218-z.